Application | Comment | Organism |
---|---|---|
medicine | in pre-diabetic subjects, a 12-week treatment with vildagliptin markedly increases postmeal levels of active glucagon-like peptide 1 and gastric inhibitory polypeptide, improves both alpha- and beta-cell function, decreases postprandial hyperglycemia and decreases A1C levels. Vildagliptin is well tolerated and weight neutral and does not cause hypoglycemia | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
vildagliptin | in pre-diabetic subjects, a 12-week treatment with vildagliptin markedly increases postmeal levels of active glucagon-like peptide 1 and gastric inhibitory polypeptide, improves both alpha- and beta-cell function, decreases postprandial hyperhlycemia and decreases A1C levels. Vildagliptin is well tolerated and weight neutral and does not cause hypoglycemia | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
glucagon-like peptide 1 + H2O | - |
Homo sapiens | ? | - |
? |